Valuation: Vertex Pharmaceuticals Incorporated

Market Cap 131B 119B 110B 99.68B 187B 12,091B 197B 1,334B 530B 6,604B 490B 480B 20,727B P/E 2026 *
35.9x
P/E 2027 * 29.6x
Enterprise Value 128B 116B 107B 97.58B 183B 11,836B 192B 1,306B 519B 6,465B 480B 469B 20,289B EV / Sales 2026 *
9.64x
EV / Sales 2027 * 8.35x
Free-Float
99.73%
Yield 2026 *
-
Yield 2027 * -
1 day-1.08%
1 week-4.38%
Current month-7.85%
1 month-1.81%
3 months-6.03%
6 months+18.79%
Current year+13.60%
1 week 513.8
Extreme 513.8
549.56
1 month 509.2
Extreme 509.205
568.67
Current year 412.27
Extreme 412.27
568.67
1 year 412.27
Extreme 412.27
568.67
3 years 346.28
Extreme 346.285
568.67
5 years 179.96
Extreme 179.96
568.67
10 years 71.46
Extreme 71.46
568.67
Manager TitleAgeSince
Chief Executive Officer 53 31/03/2020
Director of Finance/CFO 57 09/04/2019
Chief Tech/Sci/R&D Officer - 30/06/2025
Director TitleAgeSince
Director/Board Member 66 31/12/1997
Chairman 70 30/04/2012
Director/Board Member 57 17/06/2015
Date Insider Type Main position Quantity % Market Cap. Importance
20/10/26 Free

Director

795 0.0003%
15/10/26 Free

Director

29 0.0000%
15/10/26 Free

Director

93 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
-1.08%-4.38%+20.68%+45.17% 131B
-0.30%-6.68%+27.12%+127.32% 1,200B
+1.25%-5.35%+32.65%+78.98% 651B
+0.94%-2.99%+21.13%+106.30% 506B
-0.60%-1.95%+25.73%+67.00% 377B
+0.69%-9.50%+36.78%+30.83% 330B
+0.41%-4.70%+24.18%+50.18% 288B
+0.81%-4.08%-2.95%+31.59% 272B
-0.15%-6.45%+29.06%+65.76% 236B
-0.06%-0.98%+31.42%+122.83% 206B
Average +0.19%-4.72%+24.58%+72.60% 420B
Weighted average by Cap. +0.26%-5.17%+25.86%+86.55%

Financials

2026 *2027 *
Net sales 13.26B 12.07B 11.13B 10.12B 18.99B 1,228B 19.95B 135B 53.82B 671B 49.74B 48.69B 2,104B 14.65B 13.35B 12.3B 11.19B 20.99B 1,357B 22.06B 150B 59.49B 741B 54.98B 53.82B 2,326B
Net income 3.66B 3.33B 3.07B 2.79B 5.24B 339B 5.51B 37.37B 14.85B 185B 13.73B 13.44B 581B 4.52B 4.12B 3.79B 3.45B 6.47B 418B 6.8B 46.15B 18.34B 229B 16.95B 16.6B 717B
Net Debt -2.76B -2.51B -2.32B -2.11B -3.95B -255B -4.15B -28.18B -11.2B -140B -10.35B -10.13B -438B -8.16B -7.43B -6.85B -6.23B -11.69B -756B -12.29B -83.37B -33.14B -413B -30.62B -29.98B -1,296B
Projected Income Statement - Annual - Vertex Pharmaceuticals Incorporated
Logo Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (62.9%), Europe (28.8%) and other (8.3%).
Employees
6,400
Date Price Change Volume
20/11/26 US$515.02 -1.08% 1,767,923
19/11/26 US$520.66 -2.94% 1,177,432
18/11/26 US$536.45 +0.42% 1,292,403
17/11/26 US$534.20 -0.67% 1,512,600
16/11/26 US$537.79 -0.15% 1,224,717
Trader
Investor
Global
Quality
ESG MSCI
AAA
MarketScreener Ratings - Vertex Pharmaceuticals Incorporated
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
515.02USD
Average target price
595.36USD
Spread / Average Target
+15.60%
  1. Stock Market
  2. Stocks
  3. VRTX Stock